Information Provided By: 
Fly News Breaks for February 25, 2020
UNH, TNDM
Feb 25, 2020 | 08:05 EDT
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes (TNDM) to $97 from $84 following quarterly results. The analyst highlights a "solid" initial guide, demonstrating the Control IQ tailwind is underway, new country opportunities and a building renewal cycle. A UnitedHealth (UNH) coverage reversal would be upside and the announced t:slim mobile app capabilities are a new differentiator that should build throughout the year, he contends. The analyst has an Outperform rating on Tandem's shares.
News For TNDM;UNH From the Last 2 Days
UNH
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
TNDM
Apr 25, 2024 | 06:13 EDT
TNDM
Apr 25, 2024 | 06:02 EDT
Leerink upgraded Tandem Diabetes to Outperform from Market Perform with a $45 price target.
UNH
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
UNH
Apr 24, 2024 | 14:22 EDT
UNH
Apr 24, 2024 | 13:51 EDT
UNH
Apr 24, 2024 | 09:02 EDT
